This is such an excellent question, which in a way should not have to be asked at all. The answer SHOULD BE....well of course it will be considered and that any rational/objective review will certainly result in AVXL being on the short list. BTW, being on the funded list automatically moves AVXL up in the queue of companies to look at.
Considering that these are the same geniuses that managed the last 30+ years I am not holding my breath. GREAT QUESTION.
Not sure where ATCT funds specific trials. Thought the NIH funding was for infrastructure. Wouldn't trial funding come from other sources? To be sure the intent of developing the infrastructure is almost shadow funding by its nature. However, I do not think they will be directing funds to individual companies or trials.